

QOPI® CERTIFICATION TRACK Round 2 2020 MEASURE SUMMARY

***Note: Measure 27 has been retired and replaced with measures 30 & 31 starting Round 2 2020**

MODULE	MEASURE	MEASURE	NQF Endorsed Measure
CORE	1	Pathology report confirming malignancy*	
CORE	2	Staging documented within one month of first office visit*	NQF Endorsed #0386 (adapted)
CORE	6	Pain addressed appropriately (defect-free measure 3, 4a, and 5) *	NQF Endorsed #0383 (adapted)
CORE	6a	Pain assessed on either of the two most recent office visits*	NQF Endorsed #0383/#0384 (adapted)
CORE	9	Documented plan for chemotherapy, including doses, route, and time intervals*	
CORE	10	Chemotherapy intent (curative vs. non-curative) documented before or within two weeks after administration*	
CORE	11	Chemotherapy intent discussion with patient documented*	
CORE	13oc4a	Documented plan for oral chemotherapy: Dose*	
CORE	13oc4b	Documented plan for oral chemotherapy: Administration schedule (start day, days of treatment/rest and planned duration) *	
CORE	16	Patient consent for chemotherapy (combined measure 14 or 15) *	
CORE	21aa	Smoking status/tobacco use documented in past year*	NQF Endorsed #0028 (adapted)
CORE	24	Patient emotional well-being assessed by the second office visit*	
CORE	25	Action taken to address problems with emotional well-being by the second office visit*	
CORE	25b	Height, Weight, and BSA documented prior to chemotherapy*	
SMT	30	Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents*	
SMT	31	Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents – Avoidance of Overuse (Lower Score – Better)*	
SMT	33	Infertility risks discussed prior to chemotherapy with patients of reproductive age*	
BR	53	Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage IA (T1c) and IB - III ER/PR negative breast cancer*	NQF Endorsed #0559 (adapted)

QOPI® CERTIFICATION TRACK Round 2 2020 MEASURE SUMMARY

***Note: Measure 27 has been retired and replaced with measures 30 & 31 starting Round 2 2020**

MODULE	MEASURE	MEASURE	NQF Endorsed Measure
BR	54	Test for Her-2/neu overexpression or gene amplification*	NQF Endorsed #1878 (adapted)
BR	59	Tamoxifen or AI received within 1 year of diagnosis by patients with AJCC stage IA (T1c) and IB - III ER or PR positive breast cancer*	NQF Endorsed #0220/#0387 (adapted)
CRC	66	CEA within 4 months of curative resection for colorectal cancer*	
CRC	68	Adjuvant chemotherapy received within 2 months of diagnosis by patients with AJCC stage III colon cancer*	NQF Endorsed #0223/#0385 (adapted)
CRC	73	Colonoscopy before or within 6 months of curative colorectal resection or completion of primary adjuvant chemotherapy*	NQF Endorsed #1859 (adapted)
CRC	74	RAS (KRAS and NRAS) testing for patients with metastatic colorectal cancer who received anti-EGFR MoAb therapy*	NQF Endorsed #1860 (adapted)
NSCLC	84	Performance status documented for patients with initial AJCC Stage IV or distant metastatic NSCLC*	
NSCLC	88	Patients with Stage IV NSCLC with adenocarcinoma histology with an activating EGFR mutation or ALK gene rearrangement who received first-line EGFR tyrosine kinase inhibitor or other targeted therapy *	
GYNONC	94	Platin or taxane administered within 42 days following cytoreduction to women with invasive Stage I (grade 3), IC-IV ovarian, fallopian tube, or peritoneal cancer*	NQF Endorsed #0218